Rapamycin, mTORC1 complex inhibitor (ab120224)
Key features and details
- mTORC1 complex inhibitor
- CAS Number: 53123-88-9
- Soluble in DMSO to 50 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Rapamycin, mTORC1 complex inhibitor -
製品の詳細
mTORC1 complex inhibitor -
別名
- Sirolimus
-
生理活性の詳細
mTORC1 complex inhibitor. Binds with FKBP-12 to inhibit mTOR (mammalian target of rapamycin) C1 signaling. Induces autophagy in vitro and in vivo.
-
CAS 番号
53123-88-9 -
構造式
製品の特性
-
体系名
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25, 26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone -
分子量
914.18 -
分子式
C51H79NO13 -
PubChem 登録番号
9854380 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 50 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
O[C@@H]1CC[C@@H](C[C@H]1OC)C[C@@H](C)[C@H]2OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@]3(O)O[C@H](C[C@H](OC)C(C)=CC=CC=C[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=C[C@@H](C)C(=O)C2)CC[C@H]3C -
由来
Synthetic
-
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120224の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| 特記事項 |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
画像
-
Chemical Structure - Rapamycin, mTORC1 complex inhibitor (ab120224)2D chemical structure image of ab120224, Rapamycin, mTORC1 complex inhibitor
-
Functional Studies - Rapamycin, mTORC1 complex inhibitor (ab120224)MCF7 cells were incubated at 37°C for 1h with vehicle control (0 µM) and different concentrations of rapamycin (ab120224). Decreased expression of mTOR (phospho S2448) (ab51044) in MCF7 cells correlates with an increase in rapamycin concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 30 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab51044 at 1 µg/ml and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (23)
ab120224 は 23 報の論文で使用されています。
- Kang P et al. TRPM2-dependent autophagy inhibition exacerbates oxidative stress-induced CXCL16 secretion by keratinocytes in vitiligo. J Pathol 262:441-453 (2024). PubMed: 38186269
- Sarkar A et al. Early loss of endogenous NAD+ following rotenone treatment leads to mitochondrial dysfunction and Sarm1 induction that is ameliorated by PARP inhibition. FEBS J 290:1596-1624 (2023). PubMed: 36239430
- Shi H et al. Autophagy inhibition mediated by intrauterine miR-1912-3p/CTSD programming participated in the susceptibility to osteoarthritis induced by prenatal dexamethasone exposure in male adult offspring rats. FASEB J 37:e23011 (2023). PubMed: 37249374
- Wang T et al. Sirt6 enhances macrophage lipophagy and improves lipid metabolism disorder by regulating the Wnt1/β-catenin pathway in atherosclerosis. Lipids Health Dis 22:156 (2023). PubMed: 37736721
- Yi Yang et al. Naringenin and morin reduces insulin resistance and endometrial hyperplasia in the rat model of polycystic ovarian syndrome through enhancement of inflammation and autophagic apoptosis. Acta Biochim Pol 69:91-100 (2022). PubMed: 35143137